covering more types of HPV. Until 2012, the vaccine in use was the bivalent Cervarix, targeting HPV 16 and 18. Then the quadrivalent Gardasil was administered until 2023, when the nonavalent ...

One dose of a human papillomavirus (HPV) vaccine was noninferior to two doses in preventing infection, data from a randomized trial showed. In the ESCUDDO trial, which involved more than 20,000 ...

The next HPV vaccine approved in the United States, called Cervarix, is a bivalent vaccine that protects against HPV types 16 ...

While HPV-16 and HPV-18 are responsible for the ... and people who are allergic to latex should not get Cervarix.” Cervarix is the bivalent vaccine manufactured by GlaxoSmithKline.

The HPV bivalent vaccine (Cervarix) will only protect against HPV 16 and 18. The HPV quadrivalent vaccine (Gardasil) will protect against HPV types 6, 11, 16, and 18. The HPV 9-valent vaccine ...

Spikevax Bivalent Original/Omicron COVID-19 vaccine is the first bivalent ... against diseases caused by several types of the Human Papillomavirus, or HPV, including cervical cancer.

Currently, there are six approved vaccines against HPV, with one nonavalent, two quadrivalent, and three bivalent vaccines. Some are effective against the most prevalent cancer-causing genotypes ...

In the ESCUDDO trial, which involved more than 20,000 girls ages 12 to 16, one dose of both the bivalent Cervarix and 9-valent Gardasil 9 HPV vaccines provided similar protection to two doses ...